T47D/S2 Cell Line

A human breast cancer control model used to study tamoxifen sensitivity, hormone receptor signalling, and endocrine therapy resistance mechanisms. Save 30% on this cell line this summer. Use code SUM26CELL at checkout.

Contributors

Inventor Institute
Anne Lykkesfeldt Danish Cancer Society
SKU: 152109
Product description: T47D/S2 is an adherent human breast cancer cell line used as the parental control for the tamoxifen-resistant T47D/TR-1 and T47D/TR-2 cell lines. It was derived from the T47D line through adaptation to reduced serum conditions, enabling growth inhibition by tamoxifen. T47D/S2 displays a polygonal epithelial morphology and expresses both oestrogen receptor alpha (ERα) and progesterone receptor (PR). This cell line serves as a valuable model for investigating the mechanisms underlying tamoxifen resistance in hormone receptor–positive breast cancer.
Gender: Female
Conditional: Yes
Production details: Human breast cancer cell line derived from T47-D through adaptation to reduced serum conditions, glutamax and 8ug Insulin/mL.
Cellosaurus ID: CVCL_1D45
Parental cell line: T47D
Disease: Cancer
Cat. #: 152109
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer; Drug development
Organism: Human
Tissue: Breast
Gender: Female
Model: Cancer cell line
Growth properties: Adherent
Cancer Types In Detail: Breast carcinoma
Primary citation: Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
Format: Frozen
Storage conditions: Liquid Nitrogen
Shipping conditions: Dry ice
Growth medium: Phenol red free RPMI 1640 + 2% FCS + glutamax + 8ug Insulin/ml. Fetal Calf Serum (FCS) typically contains less estrogen than Fetal Bovine Serum (FBS) and is the preferred supplement for this cell line.
Subculture routine: Following thawing and counting, dilute the cell suspension with sufficient medium and distribute 5 mL each into T25 flasks to achieve a seeding density of 1.8 – 2.0 x 10^4 / cm2. Place in 37°C, 5% CO₂ incubator. Change medium after 24 hours to remove residual DMSO and then every 2-3 days. Subculture routine: Split 1:7 weekly (slow growing cell line) with Trypsin-EDTA for detachment at 37 °C for 5 minutes. Please also see detailed protocol within the Product Datasheet in the Documentation section below.
Temperature: 37° C
Atmosphere: 5% CO2
Storage medium: 10% DMSO in FCS
Mycoplasma free: Yes
Biosafety level: 1
References:

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15(1):1-15. PMID: 25885472.

Thrane et al. 2014. Oncogene. 34(32):4199-4210. PMID: 25362855.

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

Images

View Gallery
Representative pictures of sensitive parental (T47D/S2 and T47D/S5); tamoxifen (TR-1 and TR-1) and fulvestrant (182R-1 and 182R-2) resistant cell lines treated for five days with dasatinib or DMSO (control). Adapted from Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Related Tools for Cell lines

Cat. # Tool Name
151484 2fTGH Cell Line Key Info View Tool
151450 JIM3 Cell Line Key Info View Tool
151626 A375P beta6-puro Cell Line Key Info View Tool
151448 CMT 167 Cell Line Key Info View Tool
151630 PDVC57B Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.